Amgen, Inc. vs NetApp Inc. — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while NetApp Inc. trades at $199.43 (market cap $38.95B). The key difference: Amgen, Inc. is far larger — about 5.8× NetApp Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | NTAP | |
|---|---|---|
Market Cap | $224.14B | $38.95B |
Sector | Health | Technology |
52-Week High | $417.20 | $198.72 |
52-Week Low | $271.18 | $94.11 |
Enterprise Value | $267.45B | $38.10B |
Dividend Yield | 2.43% | 1.05% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →